Abstract:Dear Editor, An in-depth study of tumour vasculature can reveal the mechanisms and consequences of dysregulated tumour angiogenesis and influence new treatment strategies.1-3 Here, we establish the first pan-cancer tumour endothelial cell (TEC) atlas, characterize the shared and cancer-specific phenotypes of TECs among diverse cancer types and explore novel antiangiogenic targets. Neo-angiogenesis is an important step in tumour development and metastasis to meet the metabolic remodelling requirements of tumours.4 Anti-angiogenic therapies have been devised to inhibit pathological angiogenesis, but their limited efficiency suggests that the urgency of more effective agents is needed.5 Deconstructing TECs at the single-cell level could assist the development of new antiangiogenic drugs, but the current studies are limited by the narrowed cancer types, small sample sizes, and the relatively low abundance of endothelial cells (ECs) in tissue.1-3 Currently, there is a continuous lack of systematic studies to resolve TECs across different cancer types and in large sample sizes. We established a pan-cancer TEC atlas from the large-scale data of a total of 1.24 million cells derived from 381 high-quality samples (Figure S1A–G and Tables S1 and S2). A detailed description of this atlas is shown in the Supporting Information. Up to 63 320 ECs comprising 37 367 TECs and 25 953 normal ECs (NECs) were aggregated (Figure 1A–C). Clusters were annotated according to the biological functions of seven common EC lineages and the highest-ranking marker genes in TECs and NECs,3 and 22 functional clusters were identified (Figure 1C–E). Hepatocellular carcinoma had a high arterial infiltration, and ovarian cancer had an angiogenic infiltration (Figures 1G and S2). Differentially expressed genes and pathways were used to validate the annotations (Figure S3). This pan-cancer TEC atlas revealed a profoundly altered construction of TECs, with markedly reduced functional components such as capillary ECs and significantly elevated angiogenic components, including tip and immature ECs (Figures 2A,B and S4A,B,I). Enrichment analyses demonstrated that TECs were enriched in pathways associated with angiogenesis, EC development, and EC proliferation (Figure 2C,D). Further investigations confirmed a consistent trend of decreasing capillary ECs and increasing angiogenic ECs across almost all cancers (Figure 2E–J). Scavenging FCGR2B+ capillary ECs were abundant in normal liver and lung6 but were substantially diminished in liver and lung tumours (Figure S4I–K). In addition, the proportion of tip lymphatic EC phenotypes was increased in tumours, indicating enhanced lymph-angiogenesis in tumours (Figure 2G–J). Endothelial tip cells, the leading cells at the tips of vascular angiogenic sprouts, were universally increased in tumours (Figure 2); thus, comprehensive analyses of sprouting tip ECs were performed (Figure 3). Two novel tip EC clusters were newly defined, insulin receptor (INSR)+ tip ECs (C1) and PGF+ tip ECs (C2), which were verified in two independent cohorts (Figures 3A and S5). INSR+ tip ECs (C1), comprising the majority (67.6%) of all tip ECs, were significantly elevated in eight of the 12 cancer types (Figure 3B,C). The marker gene of this cluster, INSR, is a critical metabolic gene.7 INSR+ tip ECs expressed peaked levels of VEGFR1 and VEGFR2 (Figure 3D), suggesting their relation with angiogenesis. The expression of INSR in tumour vasculature was examined across diverse cancer types. Immunohistochemistry staining in 20 types of cancers exhibited a consistent amount of robust enrichment of INSR in TECs (Figure S6B,C). Further multiplex immunofluorescence staining of CD31, INSRβ, and VEGFR2 in 20 types of cancer tissues verified the uniform colocalization of INSRβ staining with CD31/VEGFR2 staining (Figure 3E). This universal pan-cancer expression of INSR bolstered the credibility of INSR as a pan-cancer angiogenic marker. The enrichment analyses of INSR+ tip ECs yielded pathways related to angiogenesis and IGF binding that were upregulated (Figure 4A,B). In the IGF pathway, both IGF1 and IGF2 were significantly correlated with classical EC markers in multiple cancers, but the correlations between IGF1R or IGF2R and EC markers were weak (Figures 4C and S6A). INSR, another high-affinity receptor of IGFs,8 was expressed exclusively in tumour ECs and identified as a novel angiogenic marker (Figure 4D,E). INSR strongly correlated with EC markers in multiple cancers (Figure S7A), indicating the pro-angiogenic effects of IGFs via INSR. Further in vitro matrigel angiogenesis assays demonstrated that overexpression of INSR significantly enhanced the tube-forming capacity (Figure 4F,H), while INSR knockdown impaired the formation of tubes (Figure 4G,I), supporting the enhancement of angiogenic capacity via INSR. Then, we examined the in vivo therapeutic efficacy of BMS-754807, a small-molecule inhibitor of INSR,9 in subcutaneous tumour models of two mouse cell lines. Both LLC and CT26 tumours responded significantly to INSR inhibition, whether or not it was combined with chemotherapy. The efficacy reached maximum when chemotherapy, VEGFR2 antibody and INSR inhibitor were administered simultaneously (Figures 4J–Q and S7B,C). We further used an orthotopic LLC model followed by flow cytometry to investigate the impacts of the INSR inhibitor on EC abundance (Figure 4N–Q). The INSR inhibitor significantly reduced the abundance of ECs in orthotopic tumours, regardless of whether chemotherapy was combined (Figures S7H and 4O). In addition, the INSR inhibitor could significantly lower the expression levels of VEGFR2 and INSR on ECs, and the effects were enhanced when αVEGFR2 was combined (Figure 4P,Q). Intriguingly, chemotherapy increased the EC abundance in orthotopic tumours, and the effects could be reversed by the INSR inhibitor (Figure 4O). When comparing all EC clusters, we discovered that mature venous ECs expressed the highest level of MHC-II molecules (Figure S8A,B). In two scRNA-seq immunotherapy cohorts, we observed remarkably enriched MHC-II+ mature venous ECs in patients with a better response to immunotherapy (Figure S8C–H). In addition, MHC-II+ mature venous ECs were also linked with a significantly favourable prognosis after immunotherapy (Figure S8I–N). In conclusion, we systematically characterized TECs across malignancies. Dissection of TECs revealed a novel INSR-expressing tip TEC cluster as the predominant angiogenic driver. The pervasive presentation on angiogenic TECs implicates INSR as an angiogenic hallmark. The in vitro and in vivo experiments further verified INSR as a novel antiangiogenic target. Furthermore, MHC-II+ mature venous ECs were linked with a better immunotherapy response. Our study of pan-cancer TECs may facilitate the development of innovative antiangiogenic agents. Dr. Ze-Xian Liu, Rui-Hua Xu and Huai-Qiang Ju had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr. Yongqiang Zheng, Yi-Qian Pan and Kun Liao contributed equally to this work as co-first authors. Conception and design: Rui-Hua Xu and Ze-Xian Liu. Supervision: Rui-Hua Xu and Ze-Xian Liu. Acquisition, analysis, or interpretation of data: Yongqiang Zheng, Kai Yu, Yanxing Chen and Ze-Xian Liu. Drafted the manuscript: Yongqiang Zheng, Yi-Qian Pan, Yuqing Deng, Huai-Qiang Ju, Ze-Xian Liu and Rui-Hua Xu. Experiments: Yi-Qian Pan, Kun Liao, Yuqing Deng, Qinian Wu, Hui Sun and Huai-Qiang Ju. Critical revision of the manuscript for important intellectual content: All authors. Software: Yongqiang Zheng, Kai Yu, Yanxing Chen and Hengying Pu. Statistical analysis: Yongqiang Zheng, Kai Yu and Ze-Xian Liu. Obtained funding: Ze-Xian Liu and Rui-Hua Xu. We are grateful to all the authors who shared their data online. The flow chart in Figure 1A and the Graphical Abstract were optimized with the help of Colouring (Guangzhou) Co., Ltd. This study was supported by the National Key R&D Program of China (2021YFA1302100), National Natural Science Foundation of China (81972239, 82321003, 81930065, 82173128 and 32370698), Science and Technology Program of Guangzhou (202206080011), Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096), Tip-Top Scientific and Technical Innovative Youth Talents of Guangdong Special Support Program (2019TQ05Y351), Young Talents Program of Sun Yat-sen University Cancer Center (YTP-SYSUCC-0029), Guangdong Basic and Applied Basic Research Foundation (2023B1515040030), CAMS Innovation Fund for Medical Sciences (CIFMS) (2019-I2M-5-036), Chih Kuang Sholarship for Outstanding Young Physician-Scientists of Sun Yat-sen University Cancer Center (CKS-SYSUCC-2023001), and Cancer Innovative Research Program of Sun Yat-sen University Cancer Center (CIRP-SYSUCC-0004). The authors declare no conflicts of interest. This study wasapproved by the Institutional Review Board of the Sun Yat-sen University CancerCentre (No. B2023-074-01). The animal experiments in this study were approvedby the Animal Experiments Committee of Sun Yat-sen University (No.L025501202303007). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Dear Editor, Esophageal squamous cell carcinoma (ESCC) is the predominant subtype of esophageal cancer in Asia, which is characterized by rapid invasion and metastasis and has a poor clinical outcome.1 Recently, the genetic landscape2 and single-cell atlas3, 4 of ESCC have been unveiled; however, the vascular heterogeneity in ESCC remained unknown. Our study fully characterized the endothelial cells in ESCC, which may have implications for the development of anti-angiogenic therapies (AATs) in ESCC. To interrogate the cellular heterogeneity and evolutionary trajectory, we performed scRNA-seq on cells from three geospatial regions, including 20 tumours and 31 matched normal esophageal tissues with defined distances from the tumour edge (i.e., adjacent, 2 cm from tumour edge; distant, 5 cm from tumour edge; Figure 1A). After quality control, a total of 206 380 cells were included for subsequent analysis (Figure S1A). Cells clustered into 10 major cell lineages (Figure 1B), highlighting the gene signatures of major cell lineages (Figure 1C). These cells were adequately derived from all geospatial regions, and the compositions of lineages varied across the ESCC and peri-tumoural tissue (Figure 1D). Hierarchical clustering revealed that the expression patterns of epithelial cells, fibroblasts, and endothelial cells from the tumours were different from those of cells from their matched geospatial normal counterpart (Figure 1E; Figure S1B). Analysis of geospatial cell composition identified topological gradients of the cell lineages from the distant tissue to tumours (Figure 1F–G). To further investigate the taxonomy of ECs in ESCC, we re-clustered vascular ECs and identified 16 EC subtypes (Figure 2A). We annotated the clusters based on the expression of canonical gene signatures of artery, capillary, vein, and tumour endothelial cells (TECs) (Figure 2B). The cell composition of EC subtypes varied across different regions, but the angiogenic TECs were highly enriched in ESCC (Figure 2C), for example, COL4A1+ tip cells (p < .05; Figure 2D). We found that tip cells in ESCC account for over 25% of ECs in tumours, compared to previously reported tip cells compromised only a minority (<10%) of ECs in lung tumour.5 However, the correlation between TEC composition and cancer stage was insignificant in our study (Figure S2A), which deserved further investigation. We further identified COL4A1+ tip cells, RGCC+ stalk cells, and UNC5B+ arteries with highly expressed genes associated with collagen modification, angiogenesis, and vascular endothelial growth factor (VEGF) signaling (Figure 2E; Figure S2B, C) in line with previous observations.5, 6 Notably, these angiogenic TECs were mostly derived from tumour tissues (Figure 2E) and highly expressed VEGFR1 and VEGFR2 (Figure 2F), which were promising targets for anti-VEGF therapy.7 Besides, by co-localizing COL4A1 and CD31 using immunostaining, it was validated that tip cells were present in the tumours rather than in adjacent samples (Figure S2D). Last, the validation of a high fraction of TECs and the interpretation of other EC subtypes were present in supplementary. Multi-regional or geospatial analyses have been employed to interrogate cell evolution,8 so we investigate the differentiation trajectory of tip cells in ESCC. The pseudo-time analysis showed that RGCC+ stalk cells, UNC5B+ arteries, and SELE+ veins are the sources of the COL4A1+ tip cells (Figure 3A), demonstrating that tip cells originate from different vascular beds. Focusing on the formation of tip cells, the dynamic model inferred a cascade of gene expression events underlying the process (Figure 3B). For example, genes associated with collagen modification (COL4A1 and COL4A2) and angiogenesis (PDGFB) were highly expressed in the early stage, while tumour-associated marker PMEPA1 was expressed in the late stage. Next, we investigated the underlying activated transcription factors that drive the maturity of tip cells. We highlighted that ETS1 regulons were activated in angiogenic TECs (Figure 3C), as previously reported ETS1 is essential for angiogenesis.7, 9 Besides, the expression of these regulons was significantly associated with the gene of dynamic events of tip cells (e.g., VEGFR1, COL4A1, and FAM167B), suggesting the regulons activate the gene expression of tip cells in the early stage (Figure 3D). Last, we found the high expression of the dynamic event's genes, FAM167B and DYSF, had shorter overall survival in ESCC patients (Figure 3E). In summary, these results identified dynamic trajectories and distinct transcription factors that highlighted ETS1 may drive the differentiation processes from different EC subtypes to tip cells, and provided a rich resource to encourage further functional validation. Finally, we integrated single-cell data of ECs from ESCC and non-small cell lung cancer (NSCLC)5 to compare the EC phenotypes (Figure 4A). The visual plot showed that cells were well mixed rather than grouped by dataset- or tissue-specific conditions (Figure 4B). We observed that tip cells of lung and esophagus represent substantial transcriptome similarity. The hierarchical clustering showed that the tip cells of ESCC and NSCLC were more likely to cluster together (Figure 4C). Also, the marker genes of EC subsets between ESCC and NSCLC were compared, showing a significant overlap of marker genes between angiogenic EC clusters in lung- and esophageal cancer (Figure 4D). Besides, we calculated the potential regulon of TECs in lung, revealing regulon ETS1 was also upregulated in tip cells in lung (Figure 4E). Furthermore, the upregulation of regulons KLF2 and ELK3 were associated with shorter overall survival in LUSC patients (Figure 4F). In summary, these results revealed a comparable transcriptome overlap of angiogenic ECs in ESCC and NSCLC. In conclusion, our results provided a geospatial framework for characterizing the vascular architecture in ESCC, highlighting the diverse EC identities, differentiation trajectories, and high resolution of cell heterogeneity. Our analysis identified ETS1 as key regulons that regulate the expression events in tip cell differentiation, which provided a rich resource to encourage further functional validations on associations between TFs and angiogenesis. Our integrated analysis of lung and esophagus identified substantial transcriptome similarity of tip cells across tumour type, suggesting the potential clinical implications of AATs in ESCC.10 (A) Quality control of single-cell data by filtering aberrantly high gene count and extensive mitochondrial contamination. Violin plot showing the number of unique genes (nFeature_RNA), the total number of molecules (nCount_RNA), per cent of mitochondrial RNA and ribosome RNA of datasets before (left) and after (right) the quality control. (B) Dendrograms showing hierarchical relationships of cells among the geospatial locations based on the computed Euclidean distance using transcriptomic features. Dendrograms are shown for other cell types by patients. (A) Box plot showing the cell proportion of tip cells by cancer stages of ESCC patients. Statistical method is Wilcox-test, p > .05. (B and C) Different colored bar plots showing the functional pathways enriched by gene signatures of tip cells and stalk cells. (D) Representative micrograph of COL4A1+ tip cells for ESCC tumour (left) and corresponding adjacent tissue (right) section immunostained for CD31 and COL4A1. Nuclei were stained with DAPI. Scale bar, 50 μm. (A) Stacked bar plot showing the relative fraction of EC subtypes in tumour region of digestive system tumour. Different color indicated different EC subtype. (B) Stacked bar plot showing cell proportions of detailed EC subtypes in another ESCC dataset (GSE160269). (C) UMAP visualization showing EC subtypes colored by assigned cell types. (D) Bubble plot showing the expression level and the expressed cell proportions of selected gene signatures. (A) Bubble plot showing the expression level and the expressed cell proportions of selected gene signatures in arteries. (B) Colored bar plots showing the functional pathways enriched by gene signatures of UNC5B+ artery. (C) Bubble plot showing the expression level and the expressed cell proportions of selected gene signatures in capillaries. (D and E) Colored bar plots showing the functional pathways enriched by gene signatures of CA4+ capillary and SOCS3+ capillary. (F) Bubble plot showing the expression level and the expressed cell proportions of selected gene signatures in veins. (G to L) Colored bar plots showing the functional pathways enriched by gene signatures of HLA+ vein (G), IL6+ vein (H), CPE+ vein (I), ISG15+ vein (J), ACTG1+ post-capillary vein (K), and SELE+ vein (L). (A) Box plot showing the cell proportion of tumour-associated ECs increased by geospatial regions. Statistical method is Wilcox-test, p < .05. (B) Box plot showing the cell proportion of immunomodulatory veins decreased by geospatial regions. Statistical method is Wilcox-test, p < .05. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Pan-cancer Landscape of Tumour Endothelial Cells Pinpoints Insulin Receptor As a Novel Antiangiogenic Target and Predicts Immunotherapy Response

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues

Pan-cancer integrative analyses dissect the remodeling of endothelial cells in human cancers

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Therapeutic Efficacy of ECs Foxp1 Targeting Hif1α-Hk2 Glycolysis Signal to Restrict Angiogenesis

Single-cell Sequencing of Multi-Region Resolves Geospatial Architecture and Therapeutic Target of Endothelial Cells in Esophageal Squamous Cell Carcinoma

Tumour vasculature at single-cell resolution

The Pan-tumor Vasculature Under the Transcriptomic Magnifying Glass

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Transcriptomic Landscape of Endothelial Cells: Key Tumor Microenvironment Components Indicating Variable Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

Abstract 6829: Identification of immune suppressive features in tumor-associated endothelial cells (TECs) in EGFR-mutant non-small cell lung cancer via single-cell RNA sequencing

Pan‐Cancer Single‐Cell Transcriptomic Analysis Reveals Divergent Expression of Embryonic Proangiogenesis Gene Modules in Tumorigenesis

Single Cell Analysis Reveals Intra‐tumour Heterogeneity, Microenvironment and Potential Diagnosis Markers for Clear Cell Renal Cell Carcinoma

Tumour endothelial cells for translational research and therapeutics

Single cell atlas of kidney cancer endothelial cells reveals distinct expression profiles and phenotypes

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates.

Association of Angiogenesis Gene Expression With Cancer Prognosis and Immunotherapy Efficacy

Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor, volume III

Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma

Comprehensive Analysis of Tumor-Infiltrating Immune Cells and Relevant Therapeutic Strategy in Esophageal Cancer

Abstract PD10-08: Remodeling the inflammatory breast cancer tumor microenvironment to enhance immunotherapy: Novel therapeutic development